Ivermectin B1a aglycone is an acid degradation product produced by hydrolysis of the disaccharide unit of ivermectin. It can inhibit nematode larval development, but does not cause paralytic activity.
Ivermectin B1a monosaccharide is produced by selective hydrolysis of the terminal saccharide unit of ivermectin. It can inhibit nematode larval development, but does not cause paralytic activity. This compound has been used as a probe to detect some types of ivermectin resistance.
Avermectin B1a monosaccharide is a macrolide anthelmintic and monosaccharide form of avermectin B1a . It is lethal to C. elegans with a minimum active concentration (MAC) value of 0.1 μM. Avermectin B1a monosaccharide also stimulates conductance in isolated shore crab muscle.
Eprinomectin B1a, composing over 90% of the antiparasitic agent eprinomectin, is a primary component alongside eprinomectin B1b, which constitutes less than 10%. This compound is part of the avermectin family, used as insecticides and anthelmintics.
Avermectin B1a aglycone is an aglycone form of the anthelmintic and insecticide avermectin B1a . It hyperpolarizes P. crassipes muscle fibers with a minimum active concentration (MAC) value of 0.1 μM. Avermectin B1a aglycone decreases survival of C. elegans (MAC = 0.1 μM). In vivo, avermectin B1a aglycone prevents seizures induced by pentylenetetrazole in mice (ED50 = 43.9 mg/kg) without inducing deficits in rotarod performance.
2-epi-Abamectin, a degradation product of abamectin, exhibits toxicity towards the two-spotted spider mite in contact assays, possessing an LC50 value of 4 ppm. This indicates it is approximately 100-fold less potent than its precursor, abamectin.
CB1 antagonist 1 is a CB1 receptor antagonist, used in the research of obesity and metabolic syndrome, neuroinflammatory disorders, cognitive disorders, and gastrointestinal disorders, psychosis, and cardiovascular.